EUCTR2017-001551-31-FR进行中（未招募）1 期
An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 467
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Unsuitable for chemoimmunotherapy with FCR in the opinion of the investigator
- •2. Confirmed diagnosis of CD20-positive CLL or SLL that meets the CLL criteria (Hallek et al, 2008)
- •3. Binet Stage C disease, or Binet Stage B or A disease requiring treatment as defined by at least one of the criteria (Hallek et al, 2008)
- •4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- •5. Life expectancy = 6 months
- •6. Adequate bone marrow function
- •7. Patient must have adequate organ function
- •8. Female patients of childbearing potential must practice highly effective methods of contraception initiated prior to first dose of study drug, for the duration of the study, and for = 90 days after the last dose of BGB-3111, 3 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer.
- •9. Male patients are eligible if vasectomized or if they agree to the use of barrier contraception with other methods described above during the study treatment period and for = 90 days after the last dose of BGB-3111 or 3 months after the last dose of bendamustine whichever is longer.
- •10. Ability to provide written informed consent and can understand and comply with the requirements of the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 93
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 374
排除标准
- •1. Previous systemic treatment for CLL/SLL
- •2. Known prolymphocytic leukemia or history of, or currently suspected, Richter’s transformation
- •3. Clinically significant cardiovascular disease
- •4. Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast
- •5. History of severe bleeding disorder
- •6. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
- •7. Severe or debilitating pulmonary disease
- •8. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
- •9. Active fungal, bacterial and/or viral infection requiring systemic therapy
- •10. Known central nervous system involvement by leukemia or lymphoma
- •11. Underlying medical conditions that, in the investigator’s opinion, will render the administration of study drug hazardous or obscure the interpretation of toxicity or AEs
- •12. Known infection with HIV, or serologic status reflecting active hepatitis B or C infection
- •13. Major surgery within 4 weeks of the first dose of study drug
- •14. Pregnant or lactating women
- •15. Vaccination with a live vaccine within 35 days prior to the first dose of study drug
- •16. Ongoing alcohol or drug addiction
- •17. Hypersensitivity to BGB-3111, bendamustine, or rituximab or any of the other ingredients of the study drugs
- •18. Requires ongoing treatment with a strong CYP3A inhibitor or inducer
- •19. Concurrent participation in another therapeutic clinical trial.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaEUCTR2017-001551-31-SEBeiGene, Ltd.740
进行中（未招募）
1 期
A Phase 3 Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaEUCTR2017-001551-31-GBBeiGene, Ltd.680
进行中（未招募）
1 期
A Phase 3 Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomantreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaMedDRA version: 21.0Level: LLTClassification code 10003946Term: B-Lymphocytic, CLL (Kiel Classification)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10041152Term: Small lymphocytic lymphoma, consistent with CLL (Working Formulation)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001551-31-ATBeiGene, Ltd.740
进行中（未招募）
1 期
A Phase 3 Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomantreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaMedDRA version: 20.0 Level: LLT Classification code 10003946 Term: B-Lymphocytic, CLL (Kiel Classification) System Organ Class: 100000004864MedDRA version: 20.1 Level: LLT Classification code 10041152 Term: Small lymphocytic lymphoma, consistent with CLL (Working Formulation) System Organ Class: 100000004864EUCTR2017-001551-31-CZBeiGene, Ltd.600
进行中（未招募）
1 期
A Phase 3 Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomantreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaMedDRA version: 21.0Level: LLTClassification code 10003946Term: B-Lymphocytic, CLL (Kiel Classification)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10041152Term: Small lymphocytic lymphoma, consistent with CLL (Working Formulation)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001551-31-PLBeiGene, Ltd.740